

88 (5) The department may remove a board member without cause.

89 (6) The board shall nominate a board member to serve as chairperson of the board by a
90 majority vote of the board members.

91 (7) The board shall meet as often as necessary to accomplish the duties assigned to the
92 board under this chapter.

93 (8) Each board member, including the chair, has one vote.

94 (9) (a) A majority of board members constitutes a quorum.

95 (b) A vote of a majority of the quorum at any board meeting is necessary to take action
96 on behalf of the board.

97 (10) A board member may not receive compensation for the member's service on the
98 board, but may, in accordance with rules adopted by the board in accordance with Title 63G,
99 Chapter 3, Utah Administrative Rulemaking Act, receive:

100 (a) per diem at the rate established under Section 63A-3-106; and

101 (b) travel expenses at the rate established under Section 63A-3-107.

102 Section 5. Section **26-59-202** is enacted to read:

103 **26-59-202. Cannabinoid Product Board -- Duties.**

104 **§→ (1) The board shall review any available research related to the human use of a**
104a **cannabinoid product that:**

104b **(a) was conducted under a study approved by an IRB; or**

104c **(b) was conducted or approved by the federal government. ←§**

104d **§→ [(1)] (2) ←§ §→ [The] Based on the research described in Subsection (1), the ←§ board**
104e **shall evaluate the safety and efficacy of cannabinoid products, including:**

105 **(a) medical conditions that respond to cannabinoid products;**

106 **(b) cannabinoid dosage amounts and medical dosage forms; and**

107 **(c) interaction of cannabinoid products with other treatments.**

108 **§→ [(2)] (3) ←§ Based on the board's evaluation under Subsection §→ [(1)] (2) ←§ , the**
108a **board shall develop**

109 **guidelines for a physician recommending treatment with a cannabinoid product that includes a**

110 **list of medical conditions, if any, that the board determines are appropriate for treatment with §→ a**

110a **←§**

111 **cannabinoid §→ [medicine] product ←§ .**

112 **§→ [(3)] (4) ←§ The board shall submit the guidelines described in Subsection §→ [(2)] (3)**

112a **←§ to:**

113 **(a) the director of the Division of Occupational and Professional Licensing; and**

114 (b) the Health and Human Services Interim Committee.

115 ~~§~~ → [(4)] (5) ← ~~§~~ The board shall report the board's findings before November 1 of each year

115a to the

116 Health and Human Services Interim Committee.

117 Section 6. Section **58-37-3.6** is enacted to read:

118 **58-37-3.6. Exemption for possession or distribution of a cannabinoid product**